Age, median (range), years |
9 (4–18) |
Female sex, n (%) |
8 (66.7) |
Race, n (%) |
|
White |
9 (75.0) |
Unknown |
2 (16.7) |
Other |
1 (8.3) |
Body weight, median (range), kg |
34.7 (15.3–63.7) |
KPS/LPS, median (range) |
|
<80 |
3 (25.0) |
≥80 |
9 (75.0) |
Time from diagnosis, median (range), month |
5.9 (3.0–13.1) |
Primary tumor location, n (%) |
|
Pons |
8 (66.7) |
Thalamus |
2 (16.7) |
Midbrain |
1 (8.3) |
Spinal cord |
1 (8.3) |
Diagnosis, n (%) |
|
Diffuse midline glioma, H3 K27M-mutant |
8 (66.7) |
DIPG (biopsied) |
4 (33.3) |
Non-DIPG (biopsied) |
4 (33.3) |
DIPG (nonbiopsied) |
4 (33.3) |
Multifocal disease, n (%) |
|
Yes |
2 (16.7) |
No |
10 (83.3) |
Disease status, n (%) |
|
Post radiation, not recurrent |
8 (66.7) |
Recurrent |
4 (33.3) |
H3 K27M mutation method, n (%) |
|
Immunohistochemistry |
5 (41.7) |
Next-generation sequencing |
3 (25.0) |
H3.3 K27M mutation |
3 (25.0) |
H3.1 K27M mutation |
0 |
Unknown |
4 (33.3) |
Number of recurrences, n (%) |
|
0 |
8 (66.7) |
1 |
2 (16.7) |
≥2 |
2 (16.7) |
Time from prior radiation, median (range), days |
60.5 (29.0–290) |
Re-irradiation, n (%) |
3 (25.0) |
Dexamethasone daily dose, median (range), mg |
0.2 (0–4) |